Literature DB >> 6418536

Abnormal alveolar cells in monocrotaline induced pulmonary hypertension.

T Sugita, K R Stenmark, W W Wagner, P M Henson, J E Henson, T M Hyers, J T Reeves.   

Abstract

Monocrotaline given to rats causes lung injury which is followed by pulmonary hypertension. A large, abnormal intraalveolar cell has been repeatedly observed. The purpose of the present study was to define the nature of the cell and to determine how it related to the lung injury. As observed by electron microscopy, the intraalveolar cell contained numerous large, dense granules, as well as lipid whorls, extensive Golgi complexes, and many small vesicles. These cells appeared to be macrophages, possibly altered by ingestion of lipid-like material which was free in the alveolar space. Enlarged type II pneumonocytes and mast cells were seen in the alveolar walls but their appearance differed from that of the free alveolar cells. The electron microscopic findings plus the presence of Fc and C3b receptors on the cells indicated they were alveolar macrophages. When the severity of pulmonary hypertension was varied by a) giving monocrotaline to rats of varying age, b) by varying the dose of monocrotaline, or c) by varying the time interval after monocrotaline administration, the number of abnormal alveolar macrophages related to the severity of the pulmonary hypertension. When we reduced the number of circulating leukocytes by whole body radiation, monocrotaline administration was followed both by accelerated pulmonary hypertension and increased numbers of abnormal alveolar macrophages. The abnormal macrophage appeared to be a marker of the monocrotaline induced pulmonary hypertension. However, neither the abnormal macrophage nor the monocrotaline injury appeared to depend on circulating leukocytes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418536     DOI: 10.3109/01902148309061515

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  7 in total

1.  Changes in type II cell populations in monocrotaline pneumotoxicity.

Authors:  D W Wilson; H J Segall
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

2.  Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension.

Authors:  K Okada; Y Tanaka; M Bernstein; W Zhang; G A Patterson; M D Botney
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  Serum levels of soluble CD163 in patients with systemic sclerosis.

Authors:  Wakana Nakayama; Masatoshi Jinnin; Katsunari Makino; Ikko Kajihara; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Hironobu Ihn
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

4.  PAF receptor blockade inhibits lung vascular changes in the rat monocrotaline model.

Authors:  S Ono; N F Voelkel
Journal:  Lung       Date:  1992       Impact factor: 2.584

Review 5.  Estrogen paradox in pulmonary hypertension: current controversies and future perspectives.

Authors:  Soban Umar; Marlene Rabinovitch; Mansoureh Eghbali
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405

6.  Protein trafficking dysfunctions: Role in the pathogenesis of pulmonary arterial hypertension.

Authors:  Pravin B Sehgal; Jason E Lee
Journal:  Pulm Circ       Date:  2011 Jan-Mar       Impact factor: 3.017

7.  Apoptosis and inflammation associated gene expressions in monocrotaline-induced pulmonary hypertensive rats after bosentan treatment.

Authors:  Young Mi Hong; Jung Hyun Kwon; Shinkyu Choi; Kwan Chang Kim
Journal:  Korean Circ J       Date:  2014-03-12       Impact factor: 3.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.